Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
The Skin Center Dermatology Group · NCT07396168
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 4
- Target enrollment
- 10
- US sites recruiting
- 1
- Study start
- February 1, 2026
- Record last updated
- February 10, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.
Being studied: Nemolizumab
Conditions: Lichen Plano-Pilaris
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age ≥18 years.
- Clinical and/or histopathologic diagnosis of LPP.
- Presence of scalp pruritus.
- Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1.
- Ability and willingness to provide written informed consent and comply with study procedures.
- Willingness to undergo optional scalp biopsy for research purposes.
Exclusion Criteria
- Other forms of alopecia that may interfere with study assessments.
- Any systemic disease associated with hair loss.
- Inflammatory or infectious scalp disease that may interfere with the study.
- Any other conditions associated with pruritus.
- Prior use of nemolizumab.
- Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks).
- Current treatment with DMARDs (unless appropriate washout period completed; minimum 12 weeks).
- Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or
- biologics.
- Current treatment with topical or intralesional corticosteroids (unless appropriate washout period completed; minimum 4 weeks).
- Any other current treatments for hair loss (e.g., oral/topical minoxidil, PRP) unless stable for at least 6 months or 3 months washout completed.
- Allergy or hypersensitivity to nemolizumab or any excipients.
- Pregnancy or unwillingness to use highly effective contraception.
- Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.
Recruiting US locations
The Skin Center Dermatology Group
New City, NY 10956
Site contact: Peter C Friedman, MD PhD · 8453520500 · drfriedman@skincenterderm.com
Study contacts (from the official record)
- Peter Friedman, MD PhD · 8453520500 · drfriedman@skincenterderm.com